Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ITI-1001||ITI 1001|ITI1001||ITI-1001 is a DNA vaccine engineered to express peptides from the human cytomegalovirus proteins pp65, gB, and IE-1, which potentially results in enhanced antitumor immune response (PMID: 35651802).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05698199||Phase I||ITI-1001||Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)||Recruiting||USA||0|